We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+1.53%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$64.8B
AUM Growth
-$1.23B
(-1.9%)
Cap. Flow
+$395M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
28.4%
Holding
1,116
New
212
Increased
277
Reduced
389
Closed
160
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$330M |
| 2 |
CTRA
Coterra Energy
CTRA
|
+$214M |
| 3 |
Boston Scientific
BSX
|
+$204M |
| 4 |
RB Global
RBA
|
+$183M |
| 5 |
Chevron
CVX
|
+$131M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 2 |
Royalty Pharma
RPRX
|
+$187M |
| 3 |
Dover
DOV
|
+$178M |
| 4 |
Boeing
BA
|
+$168M |
| 5 |
Devon Energy
DVN
|
+$155M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.24% |
| 2 | Healthcare | 15.45% |
| 3 | Financials | 12.46% |
| 4 | Industrials | 9.23% |
| 5 | Communication Services | 8.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Copart
CPRT
$25.9B
| $1.59M | ﹤0.01% |
47,800
-6,100
| -11% | -$229K |
|
852
Pasithea Therapeutics
KTTA
$15.2M
| $1.56M | ﹤0.01% |
2,100,000
| – | – |
|
853
Immunic
IMUX
$182M
| $1.55M | ﹤0.01% |
139,860
| – | – |
|
854
Rexford Industrial Realty
REXR
$8.7B
| $1.54M | ﹤0.01% |
+47,135
| New | +$1.77M |
|
855
ATI
ATI
$27B
| $1.52M | ﹤0.01% |
10,468
| – | – |
|
856
Jones Lang LaSalle
JLL
$15.1B
| $1.52M | ﹤0.01% |
+5,000
| New | +$1.61M |
|
|
HACQU
857
HCM IV Acquisition Corp Unit
HACQU
$254M
| $1.5M | ﹤0.01% |
+150,000
| New | +$1.51M |
|
858
MP Materials
MP
$7.35B
| $1.45M | ﹤0.01% |
+30,000
| New | +$1.79M |
|
|
ADGM
859
Adagio Medical Holdings
ADGM
$10.7M
| $1.45M | ﹤0.01% |
1,258,501
| – | – |
|
860
Descartes Systems
DSGX
$5.84B
| $1.43M | ﹤0.01% |
+20,000
| New | +$1.48M |
|
861
Inovio Pharmaceuticals
INO
$79.8M
| $1.4M | ﹤0.01% |
804,958
-1,748,613
| -68% | -$2.88M |
|
862
Peapack-Gladstone Financial
PGC
$822M
| $1.38M | ﹤0.01% |
39,100
-31,467
| -45% | -$1.02M |
|
863
Larimar Therapeutics
LRMR
$416M
| $1.35M | ﹤0.01% |
+300,000
| New | +$1.2M |
|
864
Traws Pharma
TRAW
$7.43M
| $1.34M | ﹤0.01% |
730,000
| – | – |
|
865
Empire State Realty Trust
ESRT
$976M
| $1.2M | ﹤0.01% |
230,000
-555,191
| -71% | -$3.33M |
|
|
AARD
866
Aardvark Therapeutics
AARD
$138M
| $1.13M | ﹤0.01% |
+300,000
| New | +$3.11M |
|
867
Park Hotels & Resorts
PK
$2.97B
| $1.05M | ﹤0.01% |
+100,000
| New | +$1.1M |
|
868
iRhythm Holdings
IRTC
$3.59B
| $978K | ﹤0.01% |
8,289
-116,711
| -93% | -$16.8M |
|
|
CBK
869
Commercial Bancgroup
CBK
$454M
| $932K | ﹤0.01% |
+35,825
| New | +$919K |
|
|
870
Revolution Medicines Inc Warrant
RVMDW
$105M
| $895K | ﹤0.01% |
500,000
| – | – |
|
|
APC
871
ARKO Petroleum
APC
$991M
| $895K | ﹤0.01% |
+50,000
| New | +$926K |
|
872
Axcelis
ACLS
$4.12B
| $698K | ﹤0.01% |
+7,500
| New | +$664K |
|
873
Starwood Property Trust
STWD
$6.12B
| $689K | ﹤0.01% |
40,000
-1,085,000
| -96% | -$19.5M |
|
|
SHMD
874
SCHMID Group
SHMD
$270M
| $663K | ﹤0.01% |
125,000
| – | – |
|
875
CMS Energy
CMS
$23.1B
| $656K | ﹤0.01% |
+8,461
| New | +$628K |
|
Similar funds
Adage Capital Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Adage Capital Partners held 1,116 positions worth $64.8B, down 1.9% from $66.1B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Adage Capital Partners's Q1 2026 filing shows 212 new, 277 increased, 389 reduced and 160 closed positions. Its largest new stake was Takeda Pharmaceutical: 6,424,984 shares worth $119M. The largest sale was Avidity Biosciences, an estimated $190M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2026 buy was Takeda Pharmaceutical: 6,424,984 shares worth $119M.
- Adage Capital Partners added most to Revolution Medicines in Q1 2026, an estimated $330M increase.
- Adage Capital Partners's biggest Q1 2026 reduction was Royalty Pharma, cutting an estimated $187M.
- Adage Capital Partners fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Adage Capital Partners's ten largest holdings make up 28% of its $64.8B portfolio in Q1 2026.
- Adage Capital Partners opened 212 new positions and closed 160 in Q1 2026.
- Adage Capital Partners's portfolio value fell 1.9% quarter-over-quarter to $64.8B.
Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.